Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06266546 · ClinicalTrials.gov registry record · Phase 3
Prophylactic Endobronchial Tranexamic Acid to Reduce Bleeding in Transbronchial Cryobiopsy
A Phase 3 study of Hemorrhage Lung and Endobronchial Mass, sponsored by Youssef Yammine.
- Active
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06266546: Active Phase 3 study of Hemorrhage Lung and Endobronchial Mass, sponsored by Youssef Yammine.
NCT06266546 is a Phase 3 study of Hemorrhage Lung and Endobronchial Mass that is active but no longer recruiting, run by Youssef Yammine. The registered enrollment target is 100 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06266546, a Phase 3 study of Hemorrhage Lung and Endobronchial Mass, is active but no longer recruiting, sponsored by Youssef Yammine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Transbronchial cryobiopsies are common procedures used to obtain tissue samples from airways for diagnostic purposes. While these procedures are safe, there is a risk of bleeding from the biopsy site. We are conducting a research study to assess the safety and effectiveness of using tranexamic acid prior to undergoing a transbronchial cryobiopsy.
Primary Outcome
Ordinal scale of less severe to most severe 1\. No hemorrhage 2. Minor hemorrhage 3. Intermediate hemorrhage 4. Major hemorrhage
Conditions Studied
Interventions
- DRUG Tranexamic acid
Study Locations (1)
Kansas
- Ascension Via Christi - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2025-03-01 |
| Phase | Phase 3 |
What the registry record for NCT06266546 still lists
NCT06266546 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Hemorrhage Lung appearing as the primary indexed condition, and to 1 intervention - of which Tranexamic acid is the first listed.
NCT06266546 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT06266546 about?
NCT06266546 is a clinical study titled "Prophylactic Endobronchial Tranexamic Acid to Reduce Bleeding in Transbronchial Cryobiopsy". Transbronchial cryobiopsies are common procedures used to obtain tissue samples from airways for diagnostic purposes. While these procedures are safe, there is a risk of bleeding from the biopsy site. We are conducting a research study to assess the safety and effectiveness of using tranexamic acid ...
What is the current status of trial NCT06266546?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2024-03-01. Estimated completion is 2025-03-01.
What conditions does trial NCT06266546 study?
This clinical trial studies the following conditions: Hemorrhage Lung, Endobronchial Mass.
What interventions are being tested in trial NCT06266546?
The interventions under investigation include: Tranexamic acid (DRUG).
Who is sponsoring clinical trial NCT06266546?
This trial is sponsored by Youssef Yammine, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06266546 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06266546's enrollment target sits among peer trials
100 1682nd of 2000 higher than 288 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI